Intellia Therapeutics, Inc. (NTLA)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Intellia Therapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Intellia Therapeutics, Inc. (NTLA) has returned 42.60% so far this year and 80.31% over the past 12 months.

Based on dividend-adjusted daily data since May 6, 2016, NTLA's average daily return is +0.10%, while the average monthly return is +1.83%. At this rate, your investment would double in approximately 3.2 years.

Historically, 45% of months were positive and 55% were negative. The best month was Jun 2021 with a return of +116.1%, while the worst month was Oct 2018 at -40.7%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 5 months.

On a daily basis, NTLA closed higher 49% of trading days. The best single day was Jun 28, 2021 with a return of +50.2%, while the worst single day was Oct 27, 2025 at -42.2%.

Intellia Therapeutics, Inc. has an annualized alpha of 1.40%, beta of 1.78, and R² of 0.17 versus S&P 500 Index. Calculated based on daily prices since May 09, 2016.

• This stock participated in 201.97% of S&P 500 Index downside but only 169.73% of its upside — more exposed to losses than it benefited from rallies.
• R² of 0.17 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

NTLA ranks 65 for risk / return — better than 65% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.

The table below present risk-adjusted performance metrics for Intellia Therapeutics, Inc. (NTLA) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Intellia Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Intellia Therapeutics, Inc. was 96.45%, occurring on Apr 8, 2025. The portfolio has not yet recovered.

The current Intellia Therapeutics, Inc. drawdown is 92.75%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Intellia Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Intellia Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.